Wave Life Sciences (WVE) EBITDA (2016 - 2025)
Historic EBITDA for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to -$53.9 million.
- Wave Life Sciences' EBITDA rose 1261.6% to -$53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.0 million, marking a year-over-year increase of 1439.85%. This contributed to the annual value of -$97.1 million for FY2024, which is 6863.28% down from last year.
- According to the latest figures from Q3 2025, Wave Life Sciences' EBITDA is -$53.9 million, which was up 1261.6% from -$50.4 million recorded in Q2 2025.
- In the past 5 years, Wave Life Sciences' EBITDA ranged from a high of $29.2 million in Q4 2024 and a low of -$61.7 million during Q3 2024
- Over the past 5 years, Wave Life Sciences' median EBITDA value was -$37.9 million (recorded in 2022), while the average stood at -$31.1 million.
- Within the past 5 years, the most significant YoY rise in Wave Life Sciences' EBITDA was 27996.05% (2024), while the steepest drop was 95401.66% (2024).
- Wave Life Sciences' EBITDA (Quarter) stood at -$34.9 million in 2021, then decreased by 25.11% to -$43.6 million in 2022, then soared by 62.86% to -$16.2 million in 2023, then skyrocketed by 279.96% to $29.2 million in 2024, then tumbled by 284.84% to -$53.9 million in 2025.
- Its last three reported values are -$53.9 million in Q3 2025, -$50.4 million for Q2 2025, and -$46.8 million during Q1 2025.